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Abstract
The majority of pancreatic ductal adenocarcinomas (PDA) rely on the mRNA stability factor HuR 
(ELAV-L1) to drive cancer growth and progression. Here we show that CRISPR-Cas9-mediated 
silencing of the HuR locus increases the relative sensitivity of PDA cells to PARP inhibitors 
(PARPi). PDA cells treated with PARPi stimulated translocation of HuR from the nucleus to the 
cytoplasm, specifically promoting stabilization of a new target, polyADP-ribose glycohydrolase 
(PARG) mRNA, by binding a unique sequence embedded in its 3′ untranslated region (UTR). 
HuR-dependent upregulation of PARG expression facilitated DNA repair via hydrolysis of 
polyADP-ribose on related repair proteins. Accordingly, strategies to inhibit HuR directly 
promoted DNA damage accumulation, inefficient PAR removal, and persistent PARP-1 residency 
on chromatin (PARP-1 trapping). Immunoprecipitation assays demonstrated that the PARP1 
protein binds and post-translationally modifies HuR in PARPi-treated PDA cells. In a mouse 
xenograft model of human PDA, PARPi monotherapy combined with targeted silencing of HuR 
significantly reduced tumor growth compared to PARPi therapy alone. Our results highlight the 
HuR-PARG axis as an opportunity to enhance PARPi-based therapies.
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Introduction
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer deaths in the 
United States (1, 2). Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are the best 
example of a personalized approach to treating PDA with mutations in the BRCA2/Fanconi 
anemia (FA) pathway (3–5). The primary target, PARP-1, senses and initiates DNA damage 
repair (DDR) through auto-modification, by covalently adding poly (ADP-ribose) (PAR) 
onto itself, and trans-modifying other acceptor proteins (6). PARylated PARP-1 modulates 
chromatin dynamics, recruits key DNA damage repair factors, and contributes to multiple 
pathways of DNA strand break repair (7). Poly (ADP-ribose) glycohydrolase (PARG) is a 
critical DDR-related enzyme that works in concert with PARP-1 to coordinate the efficient 
repair of DNA lesions. Through exo- and endo-glycolytic activity, PARG removes PAR 
moieties from PARP-1 and other repair factors, and is critical for restarting replication forks 
and resolving DDR (8–10). Germline or somatic defects in such DDR and related genes 
(e.g., BRCA1/2, PALB2, and FA genes) render PDA cells dependent on PARP-1 for 
Homologous Repair (HR)-driven repair, thereby making PARPi and platinum-based 
therapies promising strategies to treat a distinct subset of PDA tumors (4, 7, 11).
Despite the promise of PARPi therapies, most responsive tumors develop drug resistance 
(12, 13). Previous studies highlight adaptive resistance mechanisms such as genomic 
alterations and copy number variations (e.g., BRCA2 reversion mutations) (14, 15). 
However, genetic events selected for over time are unlikely to solely contribute to the acute 
plasticity required by cancer cells to rapidly adapt to anti-cancer agents (16). Beyond 
mutations, post-transcriptional gene regulation via RNA binding proteins (RBPs) is an 
adaptable reprogramming mechanism that may drive PARPi resistance. Our group has 
previously shown that the RBP, HuR [Hu antigen R; embryonic lethal abnormal vision-like 1 
(ELAVL1)], promotes a drug- resistant phenotype, through its stress-induced cytoplasmic 
translocation and stabilization of pro-survival mRNA targets (17–20). Herein, we report for 
the first time that the anti-tumor response to several clinically-relevant PARPi in PDA is 
regulated by the HuR-dependent stabilization of PARG.
Materials and Methods
Cell culture
PDA cell lines (MIA PaCa-2, PANC-1, Capan-1, Hs 766T, PL11) were purchased from 
ATCC (Manassas, VA, 2012). All cell lines were routinely tested for mycoplasma using 
LookOut® Mycoplasma PCR Detection Kit (MP0035 SIGMA), and only early passage 
(<10) mycoplasma- negative cell lines were used for in vitro and in vivo experiments. As 
further validation, genomic DNA extracted, PCR amplified and sent for Sanger sequencing. 
All cell lines were validated as per the expected KRAS and p53 mutation status (21). Cells 
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were cultured in standard DMEM media supplemented with 10% fetal bovine serum (FBS), 
1% L-glutamine and 1% penicillin-streptomycin (Invitrogen) at 37°C and 5%CO2. MIA 
PaCa-2 and Hs 766T with CRISPR/Cas9 knockout of HuR and MIA PaCa-2 cells with 
doxycycline inducible silencing of HuR were generated and characterized as previously 
described (18, 22).
Transfection
Transient siRNA silencing and overexpression of HuR was performed as previously 
described (20). A Myc-DDK-tagged overexpression plasmid (Origene) and commercially 
available siRNA (Dharmacon) was used for modulating PARG expression. In all 
experiments, a fraction of cells were analyzed by RT-qPCR to assess knockdown efficiency, 
and all functional assays were performed 48 hours after transfection.
RT-qPCR and mRNA expression analysis
Cells transfected with indicated siRNAs for 48 hours were directly harvested (mRNA 
steady-state level) or treated with 5μg/mL Actinomycin D and harvested at indicated time 
points. Total RNA extraction, reverse transcription and quantitative PCR (RT-qPCR) 
performed as previously described (18). Relative quantification was performed using the 
2−ΔΔCt method. For detecting PARG isoforms, primers were designed to amplify exclusive 
regions based on splice sites (available upon request) and a qPCR protocol was modified 
accordingly to accommodate variations in amplicon size and annealing temperatures.
Immunoblot analysis
Cytoplasmic and nuclear extracts were isolated using the NE-PER Nuclear and Cytoplasmic 
Extraction Kit (Thermo-Scientific) as per manufacturer’s instructions. Total protein extracts 
were isolated and immunoblotting was performed as previously described (18). Primary 
antibodies used are HuR (3A2, 1:10,000; Santa Cruz Biotechnology), glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; 1:10,000; Cell Signaling Technology), poly ADP-
ribose polymerase (PARP-1; 1:1000; Santa Cruz Biotechnology), PAR (1:1000; Trevigen), 
PARG (1:1000; Millipore, Abcam), Caspase-3 (1:1000; Cell Signaling Technologies), 
γH2AX (1:1,000; Millipore), Lamin A/C (1:1,000; Cell Signaling Technology). The 
membranes were scanned and quantified using Odyssey Infrared Imaging System (LI-COR 
Biosciences).
Ribonucleoprotein Immunoprecipitation assay (RNP-IP)
PARPi treated cells were fractionated and immunoprecipitated and HuR-bound mRNAs 
were detected as previously described (17, 20, 23).
Cell growth and survival assays
Cells were seeded at 1000 cells per well in 96-well plates, and treated after 24 hours with 
increasing concentrations of indicated drugs. Short- and long- term cell survival was 
assessed by staining with Quant-iT Pico Green (Invitrogen) and soft agar colony formation 
assays respectively, and as previously described (19). IC50 values were determined through 
non-linear regression analysis.
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Chromatin Tethering
Cells cultured and treated in 150mm dishes were washed three times with ice-cold PBS, 
collected in 1mL PBS by scraping, and pelleted by spinning at 400g for 5 min. Sequential 
fractionation was performed with ice-cold 0.1% Triton X-100 in CSK buffer as previously 
described (24) and the final pellet containing (chromatin-bound proteins) and total cell 
pellets were lysed in RIPA buffer. Histone H3 is used as a positive control and GAPDH a 
negative control for the chromatin-bound fraction.
Immunoprecipitation
Cell lysates were extracted using a NP-40 lysis buffer (50mM Tris-HCl, 150nM NaCl, 1% 
NP-40, protease inhibitors). Sepharose beads coated with primary antibodies (anti-rabbit 
IgG, Santa Cruz Biotechnology, anti-rabbit HuR, MBL; anti-rabbit N-terminal PARP1, 
Active Motif) were incubated overnight, added to the precleared lysates, and rotated end-
over-end at 4°C for 4–6 hours. Beads were washed 3–5 times with lysis buffer and boiled 
with Laemmli buffer at 95°C for 10 minutes. Equal amounts of input and 
immunoprecipitated proteins were analyzed by SDS-PAGE gel electrophoresis and 
visualized by Licor.
Immunofluorescence
MIA PaCa-2 cells were cultured at 5,000 cells per 8mm coverslip. After treatment, cells 
were fixed, permeabilized, stained and mounted as previously described (Primary- γH2AX; 
Millipore; 1:500, HuR; 1:200; Santa Cruz Biotechnology; Secondary- Alexa Fluor 488 F 
anti-mouse; DAPI ProLong Gold, Life Technologies). Coverslips were imaged with a Zeiss 
LSM-510 Confocal Laser Microscope and Image J was used for foci counting, as previously 
reported (17, 20).
PAR ELISA
Total protein lysates were analyzed for PARylation using HT Colorimetric PARP/Apoptosis 
Assay (Trevigen) as per manufacturer’s instructions (25, 26).
Luciferase reporter assays
Full length PARG 3′UTR and a deletion series of putative HuR binding sites on PARG 
3′UTR was sub-cloned into the XhoI and NotI sites of the psiCheck2 vector (Promega). 
Luciferase activity was performed using Dual-Luciferase Reporter Assay System (Promega).
Apoptosis assays
Apoptosis was detected by flow cytometry using a fluorogenic substrate for activated 
caspase-3/7 in live cells (CellEvent® Caspase-3/7 Green Detection Reagent, Life 
Technologies)
Xenograft Study
Two independent sets of 6-week-old, female, athymic nude mice received 3 x 106 
Mia.shHuR cells per flank, prepared in 100μl solution comprised of 80% DPBS and 20% 
Matrigel, through subcutaneous injections. Tumors were allowed to grow to an average of 
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50mm3 (Set I: Day7; Set II: Day 23). Mice were randomized into four groups, two of which 
were started DOX chow (200mg/kg) (Bio-Serv, cat. #S3888) to induce HuR silencing. When 
tumors reached an average volume of 100mm3 (Set I: Day15, Set II: Day 23) olaparib was 
administered through intraperitoneal injection (Set I: 100mg/kg/day, Set II: 50mg/kg/day, 5 
days a week). Mouse weights and tumors were measured three times per week using an 
electronic caliper, and tumor volumes were calculated using the formula Volume = (Length 
x Width2)/2. No mice lost more than 5% of their initial body weight. Mice were sacrificed 
and tumors harvested, when one of them surpassed 1,500 mm3 (Set I: Day 36; Set II: Day 
56). Mouse protocols were approved by the Thomas Jefferson University Institutional 
Animal Care and Use Committee.
Statistical Analysis
Data and statistical analysis was performed using ISM SPSS (Version 20.0.0, IBM, Armonk, 
NY). Tumors that did not reach a calculated volume of 20mm3 by day 25 were excluded 
from the analysis (Set I: one tumor, in the combined olaparib-siHuR treatment group. Set II: 
two tumors, in the olaparib only group). Individual tumor volume fold changes were used to 
normalized tumor volume to a set starting volume of 50mm3 (Set I: at the 16. Set II: at day 
25). Log2 (Fold Change) function was used to calculate relative tumor duplications and to 
extract mean tumor duplication time: Δtime/ (tumor duplications). Tumor volumes were 
analyzed for normality of distribution using Kolmogorov-Smirnov test. Normally distributed 
continuous parameters were compared using student’s t-test and non-normally distributed 
parameters compared using a Mann-Whitney U test. Continuous parameters were presented 
as mean (± S.E). A p-value of less than 0.05 was defined as significant.
RESULTS
Genetic deletion of HuR enhances PARPi sensitivity
To assess PARPi efficacy, the IC50 values for a panel of PDA cell lines were determined. 
Consistent with previous reports, the DNA repair deficient (DDR-D) cell lines, Capan-1 
(loss of BRCA2) and Hs 766T (defective in FANCG) are significantly more sensitive to the 
PARP inhibitors olaparib (Fig. 1A), veliparib (Supp. Fig. S1A) and rucaparib, than the DNA 
repair proficient (DDR-P) PDA cell lines, MIA PaCa-2 and PANC-1 (Supp. Table 1) (27–
30).
To evaluate the role of HuR in PARPi response in vitro and in vivo, we used three strategies: 
1) siRNA targeting HuR (17, 20); 2) two characterized Clustered Regularly-Interspaced 
Short Palindromic Repeats (CRISPR)-generated PDA cell lines (DDR-P MIA PaCa-2 and 
DDR-D Hs 766T) with HuR genetically knocked out (Supp. Fig. S1B) (22); and 3) a 
doxycycline inducible siHuR cell line MIA.sh290 (18). Dose response curves from cell 
survival assays in response to several clinically relevant PARPi indicate that CRISPR-
knockout of HuR (Table 1) in both MIA PaCa-2 and Hs 766T [HuR (+/+) vs HuR (−/−)] 
caused a dramatic 20-fold decrease in sensitivity to the PARPi olaparib (Fig. 1B) and 
veliparib (Supp. Fig. S1C, Table 1). In contrast, we observed a smaller fold change in non-
PARPi agents, oxaliplatin (≤7-fold) and gemcitabine (≤3-fold) (Supp. Fig. S1C) (17). We 
validated these results with siRNA knockdown of HuR in another DDR-D cell line, Capan-1 
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(Fig. 1C, Supp. Fig. S1D, Table 1). Soft agar growth assays indicated that CRISPR knockout 
of HuR in MIA PaCa-2 and Hs 766T as well as siRNA silencing of HuR in MIA PaCa-2 and 
Capan-1 suppresses colony formation and anchorage independent growth under PARPi 
treatment (Fig. 1D, Supp. Fig. S1E). Accordingly, HuR overexpression promotes resistance 
to veliparib (2.3- fold change) (Supp. Fig. S1F). Together, these data indicate that HuR 
expression dramatically modulates the response to PARPi, independent of DDR mutational 
status.
PARPi induces cytoplasmic translocation of HuR
We previously demonstrated that veliparib causes HuR translocation in a time-dependent 
manner (17), peaking at 24 hours. (Supp. Fig. S1G). Building upon these data, we treated 
MIA PaCa-2 cells with IC50 doses of a panel of PARP inhibitors (veliparib, olaparib, 
rucaparib, niraparib, talazoparib) for 24 hours. Immunoblotting of fractionated lysates (Fig. 
1E) and immunofluorescence (Fig. 1F) indicated that cytoplasmic translocation of HuR 
significantly increased with PARPi stress while total and nuclear expression remained 
unchanged.
PARP1 binds and PARylates HuR under stress
Ke and colleagues recently demonstrated that under LPS stimulation, PARP1 directly binds 
HuR, thus resulting in its PARylation and modulating its nucleocytoplasmic shuttling as well 
as mRNA target binding(31). Though these findings were established in murine 
macrophages and human kidney cells, they could potentially have profound implications in 
carcinogenesis and tumor response, particularly in HuR-mediated stress response pathway. 
Therefore, we treated MIA PaCa2 cells with PARPi olaparib and a non-PARPi DNA 
damaging agent oxaliplatin. We demonstrated that HuR and PARP1 bind directly through 
protein-protein interactions, which is further enhanced upon stress; this results in subsequent 
PARylation of HuR (Supp Fig. S2A). Future studies will define the role of this protein-
protein interaction in PDA cells.
HuR binds PARG mRNA under PARPi stress
As an RNA binding protein, HuR promotes PDA cell survival under stress by regulating 
expression of pro-survival mRNAs (17, 19, 20, 32, 33). We performed a focused screen of 
DNA repair enzymes critical for regulating PAR turnover to identify potential mRNA targets 
(34). A 90% knockdown in HuR expression in MIA PaCa-2 cells was validated with a 40% 
down-regulation of an established HuR target, dCK (Supp. Fig. S2B)(19). The key members 
of the PARP family, PARPs 1 and 2, are unchanged demonstrating HuR’s selectivity in 
regulating DDR related transcripts (Supp. Fig. S2A). However, with HuR knockdown, we 
detected a significant 65% decrease in PARG expression, the main enzyme responsible for 
PAR degradation through its endo- and exo- glycolytic activity. Other PAR catabolizing 
enzymes such as terminal (ADP) ribose glylcohydrolase (TARG), ADP-ribosyl-acceptor 
hydrolase 3 (ARH3), Macro Domain 1 (MacroD1), Ectonucleotide Pyrophosphatase/
Phosphodiesterase 1 (ENPP1) and nudix hydrolase 16 (NUDT16) remain unchanged with 
HuR knockdown. Such HuR-dependent expression changes in PARG were further validated 
in both MIA PaCa-2 and Hs 766T HuR-CRIPSR cell lines (Supp. Fig S2C).
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To determine if these mRNA expression changes are directly due to HuR binding, we 
performed ribonucleoprotein immunoprecipitation (RNP-IP) assays (23) on cytoplasmic 
lysates of MIA PaCa-2 cells treated with respective IC50 doses of PARPi, veliparib 
(12μM/L) and olaparib (9μM/L) for 12 hours (Fig. 2A). HuR binds to PARG mRNA (11.26 
and 9.04 fold change, p ≤0.001) in response to PARP inhibition (Fig. 2B), and does not 
significantly bind to any other established PAR polymerases or hydrolases (Supp. Fig. S2D). 
These findings were validated through RNP-IP analysis of the HuR knockout MIA PaCa2 
cell line, with the isogenic control (Supp. Fig. S2E).
PARG is known to undergo alternative splicing resulting in several isoforms (hPARG111, 
hPARG102 and hPARG 99), which localize to different cellular compartments and maintain 
PAR homeostasis within the cell. We designed isoform- specific primers of PARG and 
interrogated HuR- dependent expression changes. HuR knockout MIA PaCa2 cells indicate 
a significant downregulation of all PARG isoforms (Supp. Fig. S3A), as well as increased 
mRNA binding in mRNP-IP assays (Supp. Fig. S3B). However, through protein expression 
assays, we detected and focused on the functional significance of HuR’s regulation of 
isoform hPARG111, which is primarily nuclear and responsible for the majority of PAR 
degradation (35). Despite varying levels of hPARG111 mRNA expression, the relevant PDA 
cell lines, MIA PaCa-2 and PANC-1 (DDR-P) and Capan-1, Hs 766T and PL11 (DDR-D) 
have similar PARG protein expression (Supp. Fig. 3C).
HuR knockdown decreases PARG mRNA half-life and expression under PARPi stress
HuR silenced MIA PaCa-2 cells (Supp. Fig S2D) treated with a transcriptional inhibitor 
actinomycin D over a time-course (17, 20, 36) revealed that HuR knockdown resulted in a 
significant 4–fold decrease in PARG mRNA half-life whereas GAPDH and PARP-1 mRNA 
stability were not affected (Fig. 2C, Supp. Fig. S2F)(20). Additional RT-qPCR assays 
confirmed that HuR knockdown decreases PARG expression, both in the presence and 
absence of PARPi treatment (Fig. 2D). The striking induction of PARG mRNA under 
olaparib treatment correlates with an increase in PARG protein expression in a time- (Fig. 
2E) and dose-dependent manner (Supp. Fig. S3E). Treatment with sub-IC50 doses of non-
PARPi DNA damaging agents [gemcitabine (1μM) and oxaliplatin (1μM)] for 24h resulted 
in cytoplasmic translocation of HuR and corresponding induction of PARG protein 
expression in MIA PaCa-2 cells (Supp. Fig. S3F). However, for purposes of this study, we 
sought to explore and focus on the role of PARG expression in regulating PARPi response.
HuR binds to two discrete AU-rich elements in PARG 3′UTR
HuR binds to its target mRNAs through distinct AU-rich elements (AREs) in their 3′-
untranslated regions (37). Reporter assays indicated an increase in luciferase activity in cells 
co-expressing full-length PARG 3′UTR (Luc+3′UTR) and an HuR overexpression plasmid 
(Fig. 3A), likely due to an increase in HuR’s regulation of PARG via its 3′UTR. 
Accordingly, this regulatory induction in the presence of veliparib treatment was lost when 
HuR was silenced (Fig. 3B). Computational sequence predictions identified 3 putative AREs 
within PARG 3′UTR. To further identify the minimal regulatory HuR-binding sequence, a 
deletion series of constructs derived from PARG 3′UTR (Supp. Fig. S3G) was co-
transfected with HuR overexpression plasmid in MIA PaCa-2 and Hs 766T cells (Supp. Fig. 
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S3H, S3I). Deletion of either or both sites 1 (41bp) and 3 (43bp) caused significant reduction 
in luciferase activity suggesting that both contribute to HuR’s regulation of PARG 3′UTR.
HuR regulates PARG protein expression
Irrespective of their DDR status, PDA cell lines treated with respective IC50 doses of 
olaparib showed a significant increase in basal PARG expression (as previously shown, Fig. 
2E). MIA PaCa-2 cells were transfected with HuR and PARG siRNAs for 48 hours, 
followed by treatment with IC50 doses of 3 clinically relevant PARP inhibitors for 24 hours 
(Fig. 3C). As expected, PARP inhibition induced a mild increase in PARG protein 
expression in control cells. However, HuR silencing significantly decreased PARG protein 
expression under no treatment, as well as the corresponding PARPi- treated conditions in 
both MIA PaCa-2 cells (Fig. 3C) and Hs 766T (Fig. S4A), demonstrating that PARG 
expression is mediated by HuR even in the absence of stress and independent of DDR status.
HuR regulates PARylation through PARG
Downregulation of PARG, either through HuR silencing or via a PARG-specific siRNA, 
directly affects the extent of PAR-degradation, therefore causing persistence of total PAR 
polymers i.e. PARylation, as assessed by immunoblotting (Fig. 3C, top panel) and ELISA 
(Fig. 3D). Similar results were obtained in DDR-D Hs 766T cells (Supp. Fig. S4A, S4B). 
Extensive protein expression studies also showed that PARG is significantly downregulated 
with HuR knockout in both DNA repair proficient MIA PaCa2 and deficient Hs 766T cells, 
while expression of other PAR catabolizing enzymes such as TARG1, ARH3, ENPP1, and 
MarcoD1 is not affected(Supp. Fig. S4C). Concurrently, HuR overexpression resulted in 
PARG upregulation causing a decrease in overall PAR levels in MIA PaCa-2 cells (Supp. 
Fig. S3D). These data show that HuR regulates PARG expression as well as its downstream 
function of PAR degradation.
HuR-mediated upregulation of PARG affects DNA damage response and apoptosis
To assess the effects of HuR-mediated PARG regulation on DDR, we performed relative 
quantification of γH2AX foci, a marker of DSBs in DNA. In control cells, the basal level of 
DNA damage is increased markedly upon PARP inhibition (Fig. 3E, 3F) and as previously 
shown (4). However, both HuR and PARG silencing further increased veliparib- and 
olaparib-induced DNA damage foci in DDR-P MIA PaCa-2 cell line.
The enhanced DNA damage due to HuR and PARG silencing correlated with a dramatic 
increase in apoptosis upon PARPi treatment, as indicated by staining the apoptotic 
population with a highly sensitive probe for activated caspase-3/-7 in MIA PaCa-2 and 
Hs766T cells (Fig. 4A, Supp. S5A). Our results indicate that HuR and/or PARG silencing 
enhanced PARPi- induced DNA damage and apoptosis regardless of DDR proficiency.
HuR and PARG inhibition enhances PARP trapping on chromatin by PARP inhibitors
In addition to preventing PAR production, a crucial step in DDR, PARP inhibitors can also 
behave as ‘poisons’ that induce cytotoxic accumulation of inactivated PARP-1-DNA 
complexes tethered to chromatin (38, 39), thus preventing PARP-1 release from unrepaired 
DNA strand breaks. We hypothesized that HuR stabilization of PARG in stressed cells could 
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reduce PARPi-induced ‘trapping’ of PARP-1 on chromatin, which potentially allows 
successful resolution of DNA repair and replication fork progression. We silenced HuR and 
PARG in MIA PaCa-2 cells followed by treatment with IC50 doses of olaparib, veliparib and 
rucaparib for 6 hours, and isolated soluble and chromatin-associated proteins. As above, 
HuR silencing downregulated PARG expression, and silenced HuR and PARG expression 
resulted in persistent PARylation in the presence of PARP inhibition (Fig. 4B, total protein).
Consistent with previous reports, all three PARPis resulted in increased PARP-1-DNA 
complexes (trapped PARP-1) (Fig. 4B, chromatin-bound), with olaparib and rucaparib 
exhibiting a higher PARP trapping potency. Furthermore, HuR and PARG silencing 
significantly enhanced the extent of trapped PARP-1 on chromatin, both under no treatment 
(NT) and PARPi treated conditions. Similar results in DDR- D Hs 766T (Supp. S4B) 
indicated that once again, irrespective of the presence of DNA repair mutations, HuR and 
PARG silencing enhanced PARPi cytotoxicity; in both cases, this was associated with 
increasing PARP-1 trapping on chromatin.
Prioritizing the importance of HuR and PARG expression on PARPi efficacy in PDA cells
The role of PARG expression in regulating response to PARP inhibition is further 
highlighted by over a 5-fold decrease in IC50 values of olaparib and veliparib with PARG 
silencing in MIA PaCa-2 cells respectively (Fig. 4C). Further, PARG overexpression alone 
in MIA PaCa-2 cells caused increased resistance to veliparib (Fig. 5A) and olaparib (Supp. 
Fig. S6A). Although HuR knockdown enhances sensitivity to PARPi, a rescue of PARG 
expression in HuR- silenced cells partially restores PARPi resistance. Rescuing PARG 
expression in the presence or absence of HuR, indicated efficient removal of PARylation, 
particularly in the presence of PARP inhibition shown via immunoblotting and ELISA (Fig. 
5B, 5C). As shown before (Fig. 3C, 4C, Supp. Fig. S4A, S4B), HuR inhibition in the 
presence of PARPi treatment resulted in persistence of PARylation and increased chromatin-
trapped PARP-1. Importantly, PARG rescue facilitated PARP-1 release from chromatin, 
potentially recycling PARP-1 for enhanced repair and thus contributing to a resistant 
phenotype (Fig. 5B).
Small molecule HuR inhibitor MS-444 affects PARG expression and re-sensitizes PDA cells 
to PARPi
HuR function was perturbed using a small molecule inhibitor MS-444 that prevents HuR 
dimerization, a step critical for its stress- induced translocation to the cytoplasm (40, 41). 
Immunoblotting (Supp. Fig. S6B) and immunofluorescence (Fig. 5D) show that veliparib-
induced translocation is blocked effectively by MS-444 at concentrations as low as 2.5 
μM/L. HuR inhibition via MS-444 correlates with a strong decrease in overall PARG 
expression (Fig. 5E) and an associated accumulation of total PARylation (Fig. 5F). 
Concurrently, co-treatment with a sub-lethal dose of MS-444 (5μM)(20) that prevents HuR 
translocation, but does not affect cell survival, enhanced sensitivity to veliparib (Fig. 5G) 
and olaparib (Supp. Fig. S6C, Table 1) in both MIA PaCa-2 and Capan-1 cells. 
Concurrently, MS-444 also abrogates the PARPi induced stabilization of PARG mRNA in 
both DDR-D and DDR-P PDA cells (Fig. 5H, Supp. Fig. S6D). Taken together, these data 
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indicate that small molecule inhibition of HuR inhibits PARG upregulation and function (i.e. 
PARylation), and could be potentially used to increase efficacy of PARPi.
Inducible shHuR silencing in vivo enhances olaparib-mediated suppression of PDA 
xenograft growth
Based on our in vitro findings and previously published studies emphasizing the role of HuR 
in tumor development and growth (18), we sought to investigate the role of HuR in PDA 
xenografts under PARP inhibition. We used previously characterized MIA PaCa-2 cells 
(DDR-P) in which HuR silencing can be induced upon doxycycline (DOX) treatment 
(MIA.shHuR, previously reported as MIA.sh290) (18). In vitro characterization indicated a 
decrease in sensitivity to olaparib (18-fold, p< 0.001) with DOX treatment (Supp. Fig. S7A, 
S7B). Athymic nude female mice were injected subcutaneously in their hind flanks with 
MIA.shHuR and respective groups were treated with DOX chow and olaparib (100mg/kg/
day, 5days a week). In the vehicle treated arms, the effect of DOX chow was significantly 
evident as early as day 21 (P<0.05) and continued this trend, ending with a 3.6-fold decrease 
in median normalized tumor volume as compared to mice on a normal diet (no DOX) at the 
end of the study (1212±472mm3 vs. 336±104mm3, p<0.05) (Fig. 6A, 6B, Supp. Fig. S7C). 
Olaparib treatment resulted in a significantly noticeable retardation in growth for all time 
points (P<0.05) with a final 5.6-fold decrease in tumor volume when compared to vehicle 
only (1212±472mm3 vs. 216±41mm3, P<0.01). Moreover, this effect further progressed to a 
9.3 - fold change in tumor volume when HuR is silenced (1212±472mm3 vs. 131±76mm3 
mm3, p<0.001). Tumor volumes indicate a significant reduction with HuR silencing, in both 
vehicle, as previously described (18), and olaparib treatment arms (starting at days 34 and 
24, respectively, Supp. Fig. S7C). Additionally, olaparib treatment caused a 3- fold increase 
in the duplication time of tumors, further aggravated to a ≥5-fold (p<0.001) increase with 
HuR silencing (Fig 6C). In an independent experiment at a lower dosage of olaparib 
(50mg/kg/day) treatment, similar trends of growth delay were observed in xenografted 
tumors (Supp. Fig. S7C, S7D). While low dose olaparib (50mg/kg/day) treatment did not 
significantly affect tumor growth rate (400±44 mm3 vs. 394±23 mm3, P=NS), the addition 
of HuR inhibition resulted in a significant growth delay (2.3 fold increase in duplication 
time, P<0.01) and relative decrease in tumor volume (400±44 mm3 vs. 236±24 
mm3,P<0.01).
Expression analysis of tumors harvested on day 36 (Set I) and day 56 (Set II) validated a 
significant decrease in HuR and PARG expression upon DOX induction at the mRNA and 
protein levels (Fig. 6D, 6E, Supp Fig. S7E) in both vehicle and olaparib treatment groups. 
The overall findings indicate that HuR inhibition enhances olaparib-mediated reduction of 
PDA tumor growth in vivo. These findings support the notion that HuR inhibition can 
sensitize PDA cells to PARPi therapy in vivo; even in a DDR-proficient PDA cell line.
Discussion
To date, the best personalized strategy for PDA is the synthetic lethal approach to treat 
patients’ tumors with DNA repair gene mutations. Recent Next Generation Sequencing and 
copy number variation studies estimate that a portion of PDAs may have a DDR molecular 
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signature which may render these tumors sensitive to PARPi and platinum-based therapies 
(42). In fact, ongoing clinical trials demonstrate that selected BRCA-mutated PDAs have 
progression-free survival times of 12 months or more, with response rates of over 50%(43). 
Collectively, these data are intriguing, but also point to the sobering reality that: 1) even in 
the best setting where patients are identified with BRCA2 or related gene mutations, many 
patients respond to therapy but ultimately succumb to disease (43); and 2) the majority of 
PDA patients (DDR-proficient) will most likely not benefit from PARPi therapy.
Our study directly addresses the above two unexplored points. It should be noted that even 
the model drug for personalized oncology, the tyrosine kinase inhibitor, imatinib (Gleevec), 
which targets the BCR-ABL translocation in cancer required further development of next 
generation compounds because the cancer cells frequently develop resistance to therapy 
(44). Even though mutations in BCR-ABL have been found that confer resistance to 
imatinib, many other proposed and unknown molecular mechanisms can also account for the 
relapse of disease (45). Similarly, the general mechanism by which PARPi resistance occurs 
is still unknown, though some published instances highlight reversion mutations in the 
BRCA2 gene as the proposed mechanism (14, 15, 43). Moreover, even in patients with drug 
resistance mutations, it is unknown how the cancer cell survives while selecting for a 
reversion mutation (e.g., BRCA2) (46, 47).
Based on our data, we propose that PDA cells hijack an innate rapid stress response pathway 
governed by the RBP, HuR (Fig. 6). This is the first study to show that DNA damage triggers 
activation of PARG, which is directly related to the ability of HuR to rapidly stabilize 
specific mRNA (i.e., PARG) (17, 18, 20, 32). The link between PARG activation and DNA 
repair is emerging (48–50). Our data indicate that in response to (or during) DNA damage, 
an HuR-dependent increase in PARG expression and activity (i.e. reduced PAR levels) (Fig. 
2, 3) may serve as a buffer on the total number of PAR-dependent signal factories that form 
in the cell. We hypothesize that a repair system with greater PARG activity and 
correspondingly diminished PAR production could modulate the number of PARP-1- 
dependent PAR binding sites on chromatin and improve PDA cell survival in the face of 
damage. Inversely, with diminished PARG (i.e. HuR silencing), PARP-1 could potentially 
form an excess of repair complexes that are difficult to resolve, leading to an increase in 
chromatin-bound PARP-1 (Figure 4B, Supp. Fig. S5B). This would negate an efficient DNA 
repair response. We believe that inhibition of the HuR/PARG axis enhances PARP-trapping 
on chromatin, and can be translated to improve PARPi efficacy in all PDAs, regardless of 
DNA repair status. In fact, we inhibited PARG expression using MS-444, a previously 
characterized tool for HuR inhibition (32, 41, 51). We consequently observed increased 
PARPi efficacy both in vitro and in vivo, independent of the cell line used (Fig 3C, 5A). 
Ongoing DNA repair mechanistic studies will depict the importance of the HuR/PARG axis 
on: 1) recruitment of downstream repair factors (RAD51, XRCC1) to sites of damage; and 
2) the overall efficiency of specific repair pathways (e.g., homologous recombination; DNA 
inter-strand cross-link repair) by introducing exogenous nicks and DSBs (52).
We further speculate that PARG inhibitors may work better against cancer than PARP 
inhibitors (49, 53, 54). First, due to HuR’s established overabundance in cancer (19, 55–58), 
an HuR-dependent increase in PARG in tumor versus normal cells provides a therapeutic 
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window. Second, PARG has a high specific activity for PAR degradation and helps maintain 
ADP- ribosylation dynamics within the cell (6), and thus could be a selective target. Third, 
despite their opposing enzymatic activities, PARP-1 and PARG localize to target promoters 
and regulate several common DDR- and metabolism-related genes (53, 59). Therefore, 
inhibiting PARG could potentially also target genes regulated by PARP-1, including those 
involved in cell structure, stress response, maintaining genetic stability and damage repair, 
metabolism, and GTPase regulation. Fourth, most PARPis do not selectively hit PARP-1 
activity and thus may have unwanted off target effects (60). Meanwhile, PARG is the 
primary enzyme for hydrolyzing PARylation, and thus inhibiting this enzyme in the context 
of the HuR regulated- DNA repair process (17) could potentially increase specificity and 
reduce toxicity compared to currently studied pan-PARP inhibitors. With increasing 
evidence for PARG’s role in the DDR pathway, future studies will aim to study PARG 
inhibition in PDA with small molecule inhibitors (54) and gene silencing methods. These 
studies will ultimately reveal whether targeting PARG is a better therapeutic strategy than 
targeting PARP in cancer cells.
HuR has been independently identified by multiple studies as a PAR-binding protein in 
response to DNA damage (under H2O2 or methyl methane sulfonate stimulation), indicating 
PARylation as a means of coordinating HuR-specific RNA metabolic processes (61, 62). 
The role of PARylation in facilitating nuclear export, especially in CRM1-dependent 
pathways has been well documented (63, 64) which further indicates that HuR-CRM1 
nuclear export could be modulated with PARP activity and expression. In addition to the 
striking similarities between PAR and nucleic acids, the ability of RNA recognition motifs 
(RRMs) to function as alternative PAR binding motifs (PBMs) adds an additional layer of 
complexity wherein PAR could compete with RNA and thus prevent protein functions such 
as localization, stability, splicing etc. (65). Herein, we provide support for a new mechanistic 
insight into PARP1’s regulation of HuR (Supp. Fig. S2A)(31). PARP1 activation, upon 
genotoxic stress, results in PARylated HuR which not only facilitates its cytoplasmic 
translocation, but also regulates its target binding(31). Cytoplasmic HuR selectively binds to 
several target mRNAs, which could presumably be affected by the degree of PARylation (as 
well as other PTMs such as phosphorylation, ubiquitination etc.). PARylation potentially 
contributes to HuR’s function by affecting: i) its specificity, wherein extent (length, 
branching, etc) of ADPribose polymers regulates binding affinities and ii) its selectivity, 
wherein the extent of PARylation allows differential binding to disparate pools of target 
mRNAs. HuR’s stabilization of PARG mRNA and protein expression, in addition to 
enhancing DNA repair, also supports a putative feedback loop wherein PARG dePARylates 
HuR, thus facilitating its release from target mRNAs and shuttling back into the nucleus. 
Further studies will investigate the specific PARG isoforms that regulate HuR’s function and 
vice versa, as well as further elucidate the timing and spatiotemporal organization of this 
complex process.
Finally, directly targeting HuR in PDA cells may remain our best strategy to enhance clinical 
effectiveness of PARPi, as it regulates a cadre of pro-survival transcripts (17, 19, 20, 32, 33). 
Therefore, promising attempts to target HuR are ongoing via small molecule inhibitors or a 
siHuR nanoparticle strategy (41, 66, 67) (Fig. 5) in combination with DNA damaging 
agents. Complementary studies will define and target the specific upstream mechanisms 
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(e.g. kinases) that facilitate HuR translocation to the cytoplasm in PDA (17). Finally, it will 
be interesting to determine if the HuR/PARG axis has an essential role in DNA repair in 
normal cellular and developmental biology, or if this HuR-regulated repair mechanism is 
unique to cancer cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. HuR expression regulates sensitivity to PARPi in PDA cells
Cell survival of PDA cell lines (A), HuR-knockout CRIPSR cell lines, MIA PaCa-2 and Hs 
766T [HuR(+/+) vs HuR(−/−)] (B) and HuR-silenced MiaPaCa-2 and Capan-1 cells (C) 
treated with increasing doses of olaparib for 7 days. (D) Representative images of 
MIA.HuR(+/+) vs MIA.HuR(−/−) and HST.HuR(+/+) vs HST.HuR(−/−) cells seeded and 
cultured in soft agar in the presence of respective IC50 doses of olaparib for 4 weeks. (E) 
HuR expression in MIA PaCa-2 cells treated with indicated IC50 doses of PARPi for 12hr, 
and fractionated as indicated. Lamin A/C and α-Tubulin used as controls to determine the 
integrity of nuclear and cytosolic lysates respectively. Mitomycin C used as positive control 
for cytoplasmic translocation of HuR. (F) Immunofluorescent images of HuR (green) in 
MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. 
Magnification 40X.
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Figure 2. HuR regulates PARG mRNA expression
(A) mRNP-IP assay performed with cytoplasmic fraction of MIA PaCa-2 cells treated with 
IC50 doses of veliparib (12μM) and olaparib (9μM) for 12hr, α-Tubulin used as a loading 
control for the input and a negative control for the IP samples, Lamin A/C used as a control 
to detect nuclear contamination in the input. (B) The relative binding of PARG mRNA to 
HuR, normalized to respective IgG controls, as determined by RT-qPCR using 18S rRNA as 
a loading control, dCK as positive control and PARP-1 as negative control. (C) HuR- 
silenced MIA PaCa-2 cells were treated with actinomycin D (5 μg/ml) for the indicated 
times. PARG, GAPDH and PARP-1 mRNA stability was assayed by RT- qPCR using 18S 
rRNA as a loading control. (D) RT- qPCR indicating HuR and PARG mRNA expression in 
HuR-silenced MIA PaCa-2 cells incubated in the presence of olaparib for 24hr. (E) PARG 
expression in DDR- P MIA PaCa-2 and DDR- D Capan-1 and Hs 766T cells treated with 
veliparib for indicated time points.
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Figure 3. HuR regulates PARG protein expression and function
Luciferase activity in MIA PaCa-2 cells co-expressing a luciferase reporter construct with 
PARG 3′UTR and (A) HuR overexpression or (B) HuR silencing (C) HuR, PARG and PAR 
protein expression in total lysates from HuR- and PARG-silenced MIA PaCa-2 cells treated 
with IC50 doses of indicated PARPi for 24hours, using α-Tubulin as a loading control. (D) 
ELISA indicating relative PARylation in MIA PaCa-2 cells transfected and treated as above. 
The indicated fold changes are means of three independent experiments, normalized to 
control transfected sample under no treatment (NT). (E) DSBs assessed by 
immunofluorescence staining for γH2AX (green) in MIA PaCa-2 cells transfected and 
treated as described above. (F) DNA damage foci were quantified and plotted ± SD.
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Figure 4. HuR and PARG inhibition enhances PARPi-induced apoptosis and PARP-1 trapping 
on chromatin and increases PARPi efficacy
(A) Relative number of apoptotic cells quantified and normalized to control- (NT) MIA 
PaCa-2 and Hs 766T cells. A 3hr treatment with soluble TNF-related apoptosis-inducing 
ligand (sTRAIL) is used as a positive control. (B) HuR- and PARG- silenced DDR- P MIA 
PaCa-2 cells treated with IC50 doses of indicated PARPi for 6h were harvested and 
fractionated to isolate soluble and chromatin- tethered proteins. HuR, PARG, PARP-1 and 
PAR expression analyzed, with GAPDH (total protein extract) and Histone H3 (nuclear 
chromatin- tethered fraction) as the loading controls. A representative image of one of three 
independent experiments is shown. (C) Cell survival in HuR- and PARG- silenced MIA 
PaCa-2 cells were treated with increasing doses of olaparib and veliparib for 5 days.
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Figure 5. PARG overexpression rescues HuR’s regulation of PARPi response
(A) Cell survival of MIA PaCa-2 cells co-transfected with HuR siRNA and PARG 
overexpression plasmid and treated with olaparib for 7days. (B) PARG rescue and HuR, 
PARP-1 and PAR expression validated, with GAPDH (total protein extract) and Histone H3 
(nuclear chromatin- tethered fraction) as the loading controls. (C) ELISA to quantitate 
relative PARylation with PARG rescue in HuR silenced MIA PaCa-2 cells. (D) 
Immunofluorescence of HuR (green) in MIA PaCa-2 cells treated with veliparib for 12hr, 
with or without a 6hr pre-treatment of small-molecule HuR inhibitor, MS-444. Nuclei 
stained with DAPI (blue). Magnification 40X. (E) Relative PARylation and immunoblotting 
of total protein lysates of MIA PaCa-2 cells treated with increasing dosage of MS-444, in 
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the presence of veliparib for 12h. (F) Cell survival of MIA PaCa-2 and Capan-1 cells treated 
with indicated doses of veliparib, with or without 5μM/L MS-444. (G) Luciferase activity in 
MIA PaCa-2 cells transfected with luciferase reporter constructs with PARG 3′UTR and 
incubated in the presence of MS-444 for 24 hr.
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Figure 6. HuR silencing in vivo enhances olaparib- mediated suppression of PDA xenograft 
growth
Mia.shHuR xenografts in athymic, nude mice were randomized into DOX and olaparib 
treatment groups. (A) Tumor volumes are plotted, with each point representing the mean 
± 2SE of each group, *P<0.05. Inset shows differences in number of duplications. (B) 
Representative image of mice and tumor per group. (C) Tumor duplication time (days) per 
group (D) HuR, PARG and PARP-1 mRNA expression in extracted tumors, relative to 
vehicle- treated –DOX group. Each bar represents the mean ± SEM (n = 3 per group). (E) 
HuR protein expression when tumors were harvested (day 36, n=3). (F) Working model: In 
response to PARPi stress, cytoplasmic HuR binds to and stabilizes PARG mRNA, thereby 
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increasing PARG expression and modulating PARP1-chromatin dynamics. HuR and PARG 
inhibition breaks such acute resistance by enhancing chromatin- trapped PARP-1 and 
accumulation of damaged DNA and apoptosis.
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